Challenge
In late-stage clinical development, the risk of executing your strategy is at its highest as your programme becomes larger, more complex, and more costly. You need to design and deliver pivotal programmes that secure medical endorsement, while meeting evolving regulatory and commercial requirements, as well as navigating emerging data and changes in clinical practice. When delays, quality concerns, or unclear data emerge, experienced leadership is critical to stabilise the programme, protect timelines, and preserve asset value.
How we can help you
- Development for launch strategy and full clinical development plan
- Data interpretation and product positioning
- Fractional Medical, Clinical, Regulatory and Commercial leadership
Creating development for launch strategy and delivering data on time
When you are designing and delivering large, high-cost pivotal programmes, there is very little margin for error. At this stage, the quality of strategy development and execution directly affects regulatory and commercial outcomes and downstream value. Poor operational planning can cause delays and increase costs. Suboptimal decisions can materially impact prospects for regulatory approval, timelines, and overall asset success.
tranScrip Solution
tranScrip helps you develop an integrated launch strategy that aligns pivotal trial design with regulatory expectations and commercial objectives. We help you define robust pivotal programmes that ensure clinical endpoints and evidence packages support regulatory approval and asset differentiation. Through active oversight of strategy execution and disciplined risk management across time, cost, and quality, we help you protect data integrity, timelines, and launch readiness — maximising the likelihood of regulatory and commercial success. We help you align development and regulatory positioning with health technology assessment (HTA) and payer expectations, strengthen reimbursement potential, support market access submissions, value narrative development, and partnering readiness.
What tranScrip provides
- Pivotal trial strategy and planning
- Programme design to meet regulatory and commercial requirements
- End-of Phase 2 (EOP2) global regulatory engagement to agree pivotal development plans
- Oversight of pivotal strategy execution
- Risk management (time, cost, quality)
Proven Success
Phase III Acceleration and Trial Delivery for a COVID-19 Treatment
tranScrip supported a small biotech advancing a promising COVID-19 treatment into Phase III, providing study design, regulatory expertise, CRO selection and oversight, and medical safety leadership to enable rapid start-up, inspection-ready delivery, and robust trial execution despite limited internal resource.
Understanding what the data really means
As your programme advances, scrutiny increases around how clinical, non-clinical, and CMC data are interpreted and defended. Emerging data can create uncertainty around the likelihood of marketing authorisation and commercial success, leading to hesitation, misalignment, and strategic risk at a critical stage of development.
tranScrip Solution
With senior-led expertise in data interpretation and product positioning, tranScrip helps you develop a clear strategic direction out of the complex clinical, nonclinical, and CMC data. We help you define your asset’s benefit–risk, differentiate your asset from its competitors, determine next-stage implications, align your data narrative to regulatory milestones, and produce coherent, regulator-ready documentation that strengthens approval and commercial prospects and long-term positioning of the asset.
What tranScrip provides
- Clinical, nonclinical and CMC data interpretation and implications
- Understanding implications of all data on optimal regulatory submission and approval strategy
- Regulatory engagement strategy
- Preparation for submissions, including meetings prior to New Drug Application (NDA), Marketing Authorisation Application (MAA) and Biologics License Application (BLA)
- Market access strategy including health technology assessment (HTA) and payer-focused evidence strategy and planning
- Alignment of regulatory, medical, and market access narratives
- Input into value propositions and reimbursement strategy
Proven Success
Regulatory Strategy and Scientific Advice for a Late-Stage Oncology Programme
tranScrip supported a small biotech in reassessing pivotal Phase III oncology data, combining regulatory and statistical expertise to re-analyse results, identify an alternative approach that demonstrated significance, and support scientific advice discussions with MHRA and MPA to inform future submission strategy and partnering decisions.
Positioning the programme for approval and value
As your programme approaches approval, delays, quality concerns, or unclear data can put timelines, partnerships, and asset value under real pressure. Without experienced leadership to stabilise and critically scrutinise strategy and execution, confidence can erode and progress toward regulatory and commercial milestones stall.
tranScrip Solution
tranScrip gives you experienced fractional medical, clinical, regulatory and commercial leadership to stabilise your programme as it approaches approval. Our senior leaders help you address delays, quality concerns, or unclear data with accountable oversight across data interpretation, quality of strategy execution, and regulatory strategy. We help you align teams, strengthen sponsor control, and maintain a coherent, defensible path to submission – protecting timelines, preserving asset value, and restoring confidence when scrutiny is at its highest.
What tranScrip provides
- Medical, Clinical, Regulatory and Commercial Leadership
- Medical Affairs strategy and planning
- Commercial strategy
- Market access and health technology assessment (HTA) engagement
- Partnering readiness and support
- Lifecycle management strategy
Proven Success
Late-Stage Fractional CMO Support and Clinical Data Interpretation
tranScrip provided experienced fractional CMO leadership to a biopharmaceutical company conducting a pivotal Phase III study, helping interpret complex efficacy and survival data, work closely with statisticians to address methodological artefacts, and support robust regulatory responses that contributed to EU approval, a US clinical package, and continued commercial progression.
Fractional CMO Offering
In late clinical development, tranScrip’s fractional CMOs provide senior cross-functional leadership to help clients steer pivotal programmes through complexity, interpret what the data really mean, and align medical, regulatory and commercial decisions around approval and asset value. Backed by tranScrip’s wider clinical, regulatory and commercial expertise, they help strengthen programme control, reduce risk, and maintain momentum at the point where scrutiny is highest.
